Work

Abstract PS1-08-15: Dauntless-1: A Phase 2 Clinical Trial to Evaluate PMD-026, a First-in-Class Pan-RSK Inhibitor, Combined with Fulvestrant to Overcome Resistance to CDK4/6 Inhibitors in Advanced or Metastatic HR+/HER2- Breast Cancer

Year: 2026

Type: conference-abstract

Source: Clinical Cancer Research

DOI: 10.1158/1557-3265.sabcs25-ps1-08-15

Authors: H. T. Khong, M. Beeram, R. Wesolowski, H. S. Han, N. J. Palaskas, J. Margolis, J. Peguero, N. Sharp, H. Rugo, A. Jayanthan, S. E. Dunn, J. Leveque, S. A. Wander

Institutions: Banner MD Anderson Cancer Center, South Texas Accelerated Research Therapeutics, The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, Moffitt Cancer Center, University of California, Los Angeles, Ronald Reagan UCLA Medical Center, UCLA Medical Center, City of Hope, Massachusetts General Hospital

Language: English

Topic: Advanced Breast Cancer Therapies

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W7129543007

Cites:

Cited by:

Related to: